

1 **Video Consultation in Lung Transplant Recipients during the COVID-19 Pandemic**

2 Kayser, Moritz Z.¹, Valtin, Christina¹, Greer, Mark^{1,3}, Karow, Bernd², Fuge, Jan^{1,3}, Gottlieb, Jens^{1,3}

3 ¹ Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany

4 ² Department for Hospital Innovation and Quality Management, Hannover Medical School, Hannover, Germany

5 ³ Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research
6 (DZL), Hannover, Germany.

7 **Corresponding author:** Moritz Z. Kayser, MD, Department of Respiratory Medicine, Hannover
8 Medical School, Hannover, Germany. Kayser.Moritz@mh-hannover.de

9 **Take-home message:** Implementation of video consultation was feasible during the
10 pandemic and well received by our patients. It can help bridge the gap created by COVID-19
11 in the care for lung transplant recipients and other patients with chronic respiratory diseases.

12 **Abstract:**

13 **Background:** The COVID-19 pandemic has disrupted health care systems worldwide. This
14 is due to the demand for medical resources in other areas as well as concern for the risk of
15 nosocomial SARS-CoV-2 exposure. The interruption of routine care is especially problematic
16 for patients with chronic conditions requiring regular follow-up, such as lung transplant
17 recipients. New methods like telemedicine are needed to provide care to these patients.

18 **Methods:** A retrospective analysis of video consultations (VC) in comparison to on-site visits
19 (OSV) was performed during a six-week period in a lung transplant center in Germany. VC
20 included a structured work-up questionnaire and vital sign documentation.

21 **Results:** During the 6-week study period, 75 VC were performed for 53 patients and 75 OSV
22 by 51 patients occurred. By the end of our study period, 77% of physician-patient contacts
23 occurred via VC. Overall, physician-patient consultations were reduced by 47% in
24 comparison to an equivalent time frame in 2019. In 62% of cases, VC resulted in a concrete
25 clinical decision. For two VC patients, the indication for inpatient admission was established

26 during the consultation. One COVID-19 patient in home quarantine was admitted due to
27 respiratory failure detected by VC. Patient satisfaction with VC was high.

28 **Conclusions:** By transitioning to VC, OSV for lung transplant patients during the COVID-19
29 pandemic was reduced. VC was well received by the majority of patients. This technology
30 can be adopted to provide care for a wide range of chronic illnesses.

31

32

33

34

35 Introduction

36 The emergence of the COVID-19 pandemic has disrupted health care systems worldwide¹.
37 Due to challenges posed by the virus itself as well as redistribution of health care resources
38 during the pandemic, established procedures in outpatient care for those with chronic
39 conditions have been interrupted²⁻⁴.

40 The American Medical Association (AMA) has published recommendations for the care of
41 patients during the COVID-19 pandemic, including guidelines for remote consultation⁵. In the
42 U.S., telemedicine has been successfully employed to provide care in a wide range of
43 specialties⁶. Patients with chronic respiratory conditions like chronic obstructive pulmonary
44 disease (COPD)⁷ or interstitial lung diseases (ILD)⁸ are especially endangered by COVID-
45 19^{9,10}, and traveling to specialized health care facilities puts them at additional risk¹¹. Lung
46 transplant (LTx) recipients are extremely vulnerable due to their intense immunosuppressive
47 therapy¹². LTx patients require complex, continuous medical surveillance due to
48 polypharmacy, co-morbidities, and the risk of allograft rejection¹³⁻¹⁵. Thus, follow-up care by a
49 physician with expertise in lung transplantation cannot be deferred until after the pandemic,
50 nor can it be completely replaced by home visits from general practitioners. This conundrum
51 highlights the need for new strategies.

52 Video consultations (VC) have generated increased interest following the rise of video
53 conference programs like Skype and Zoom in other sectors of the economy for professional
54 and personal use¹⁶. However, use of conventional video conferencing tools is limited by data
55 protection regulations due to concerns for patient privacy¹⁷. Recently, specialized video
56 conference software that protect doctor-patient confidentiality have become more widely
57 available, making VC an attractive option¹⁸. The object of this study is to analyze the clinical
58 impact, technical feasibility and patient satisfaction of a rapidly-implemented online VC
59 system as a partial replacement for OSV for LTx patients during the pandemic.

60

61 **Materials and Methods**

62 A retrospective analysis was performed in a high volume LTx program during the COVID-19
63 pandemic in Germany. VC was conducted from calendar week 12 (beginning on March 16th,
64 2020) to calendar week 17 of 2020. Clinical decisions made based upon VC, technical
65 feasibility, and patient satisfaction with this telemedicine program were investigated.

66 The reason underpinning each VC was categorized as either “routine surveillance” (replacing
67 a scheduled surveillance visit in a stable patient), “follow-up” (assessment of recently
68 initiated/alterd therapies or discussion of recent test results) or “clinical indication” (new
69 symptom requiring assessment). Similar categorization was performed for OSV. Prior to the
70 COVID-19 pandemic, patients were seen for on-site surveillance consultations at regular
71 intervals of 3 to 12 months, depending on the time elapsed since transplantation. Similar
72 intervals were chosen during the pandemic for surveillance VC. The decision between VC
73 and OSV was made based on clinical judgement, including whether bronchoscopy was
74 indicated. VC was preferred wherever possible. Criteria such as age or distance between
75 patient’s residence and study site were not taken into account when choosing between VC
76 and OSV

77 All LTx patients in our program that were either scheduled for routine surveillance or required
78 a consultation due to emergent clinical developments during the period between week 12
79 and week 17 of 2020 were eligible for this study.

80 VC was conducted using a video consultation tool (<https://www.sprechstunde.online/>,
81 *Deutsche Arzt AG*, Essen, Germany) developed for use in an outpatient setting and certified
82 according to the European General Data Protection Regulation (GDPR). Technical
83 requirements were a computer or smart device with a camera, microphone and speakers, as
84 well as an internet connection. Aside from the video conference function itself, we also used
85 the text chat platform and a built in GDPR-approved data file exchange tool. Patients were
86 contacted by phone to schedule an appointment for VC in advance. For first-time VC, the

87 necessary equipment and technical steps were explained during this initial telephone
88 conversation and a downloadable information sheet was provided (Supplement 1). All
89 patients received coaching by our staff via telephone in advance of their appointments in
90 addition to the written step-by-step guide. Technical guidance was estimated by our staff to
91 take 10-15 minutes per patient for the initial VC, with reduced guidance necessary during
92 subsequent VC.

93 Patients in our program are routinely equipped with a pulse oximeter and home spirometer
94 (AM1/2, eResearch Technology, Philadelphia, USA) for measurement of Forced Expiratory
95 Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC)¹⁹ and are advised to record
96 these values daily (Supplement 2). Each patient was contacted again on the day of the VC
97 by our administrative staff to arrange an exact time for the consultation. They were then sent
98 an invitation with a link to the VC online software by e-mail or text message. In addition, a
99 standardized online symptom questionnaire was sent to patients (SoSciSurvey GmbH,
100 Munich, Germany) to be filled out prior to the VC. VC was scheduled in 30-minute intervals
101 with 10 minutes for staff to prepare between appointments. During the first part of each VC,
102 the patient was asked about clinical condition, quality of life, changes in medication, and
103 symptoms of infection. Additionally, daily vital sign documentation was examined (Table 1).
104 Respiratory rate was measured using visual observation of the patient at rest by adjusting
105 the camera to view the lower thorax. Breathing actions were counted via a tap counter app
106 for one minute (<https://apps.apple.com/at/app/tap-counter-with-sets/id1247135729>, Philip
107 Braham). Additionally, pulse rate and blood oxygen saturation (S_pO_2) were measured when
108 available and home spirometry results were recorded. The second phase of the consultation
109 focused on the patient's current complaints, recent medical history and medication plan.
110 Patients were invited to ask questions and a follow-up appointment (VC or OSV) was
111 arranged. Examples of images taken during VC are shown in Figure 1 (**Not included in this**
112 **pre-print manuscript in accordance with MeDxriv's policy on patient images**).

113 After the VC, electronic documentation was completed in a clinical and scientific database
114 (FileMaker Pro, Claris International Inc, Santa Clara, CA, USA). Following the interview,
115 patients were sent an anonymous questionnaire via e-mail to ascertain their satisfaction with
116 VC. Questionnaire data was exported from SoSciSurvey into SPSS Statistics data format.
117 Statistical analysis was performed using IBM SPSS v26 (IBM SPSS Statistics, Armonk, NY,
118 USA). Categorical variables are presented as numbers (n) or percentages (%), and
119 continuous variables as median and interquartile ranges (IQR), unless indicated otherwise.
120 Statistical significance between the groups was assessed using χ^2 or Mann-Whitney U test
121 as appropriate. A P-value of <0.05 was considered statistically significant. All tests were two
122 sided. For demographic data, patients were sorted into groups depending on the type of first
123 visit during the study period.

124 This study was performed in accordance with the ethical guidelines of the 1975 Declaration
125 of Helsinki. All patients provided informed consent prior to transplantation allowing the use of
126 their data for scientific purposes, as approved by the Ethics Committee of Hannover Medical
127 School (Ethics Committee Vote Nr. 2923-2015). According to our Ethics Committee,
128 additional approval was not necessary, as data acquisition was retrospective and
129 observational, data was anonymized and the study relied on information collected as part of
130 routine care. Patients seen in Figure 1 gave written consent for the publication of their
131 images (**Not included in this pre-print manuscript in accordance with MeDxriv's policy
132 on patient images**).

133

134 **Results**

135 During the 6-week study period, 75 VC were performed for 53 patients, compared to 75 OSV
136 with 51 patients. The total number of consultations decreased by 47% during the COVID-19
137 crisis in 2020 compared to the equivalent time frame in 2019. The ratio of VC to OSV
138 increased over the course of the pandemic (Figure 2). Fourteen patients had consultations

139 by both VC and OSV during the study period. Patient characteristics are listed in Table 2.
140 Both the median time post-transplantation and the median time between consultations were
141 significantly shorter for on-site patients. The majority of OSV were required due to short-to-
142 medium term post-transplant complications necessitating bronchoscopy. Average distance
143 from patients' home to our center was similar in both groups. Geographic distribution of
144 patients is shown in Figure 3.

145 VC were distributed evenly between routine surveillance (24/75, 32%), follow-up (27/75,
146 36%) and clinical indication (24/75, 32%) (Table 3). Among OSV, 14/75 (19%) were for
147 routine surveillance, 6/75 (8%) for follow-up, and 55/75 (81%) due to clinical indication. Most
148 surveillance OSV (69%) took place during the first week of the study period. As time went on
149 and our telemedicine program became more established, a decrease in routine surveillance
150 visits conducted on-site was observed. For comparison, between calendar weeks 12 and 17
151 of 2019, 280 lung transplant recipients were seen on-site. Consultations scheduled due to
152 clinical indication accounted for 19% of visits. The remaining 81% of visits were routine
153 surveillance consultations. Of these 280 patients, 37% underwent bronchoscopy.
154 Management of airway complications accounted for 33% of all bronchoscopies performed.
155 VC due to clinical indication in 2020 were more frequent than indication-driven OSV during
156 the historical control period in 2019.

157 A minority of VC (38%) did not lead to specific action such as medication change. In 62% of
158 cases, VC led to a concrete clinical recommendation. Fourteen consultations (19%) led to
159 the recommendation for further diagnostic steps by the primary care physician such as
160 laboratory testing or imaging studies. Twenty-seven consultations (36%) led to a change in
161 medication. Three patients (4%) were brought in for an emergency OSV, due to findings on
162 VC. In each of these three cases, acute allograft rejection was subsequently diagnosed. Two
163 patients (3%) were admitted for inpatient care due to symptoms identified during VC (Table
164 2). Two VC occurred while patients were in home quarantine due to COVID-19. In one case,
165 a 47-year-old male had previously presented to his general practitioner for cough and mild

166 dyspnea and tested positive for SARS-CoV-2. We therefore arranged a VC during home
167 quarantine. On VC, we observed respiratory distress and a low SpO₂ of 81% on room air.
168 Proper function of the pulse oximeter was checked during the VC by measuring the SpO₂ of
169 the patient's father, who showed normal values. We arranged the immediate admission of
170 this patient to his local hospital. His clinical condition worsened drastically within the next 48
171 hours, culminating in ICU admission, invasive ventilation and ECMO cannulation. In another
172 case of VC leading to hospitalization, a 56-year-old female showed signs concerning for
173 pleural empyema during a VC following a similar episode three weeks earlier that had been
174 treated surgically. Due to findings on VC, this patient was admitted to our hospital for surgical
175 revision the next day.

176 Of the 53 patients who received VC, 37 (70%) responded to a questionnaire on their
177 satisfaction with the experience. Among the patients participating, the vast majority reported
178 a high degree of satisfaction. The clinical aspects of the consultation were rated more
179 favorably than the technical ones (Figure 4).

180 In addition to our written guide, which outlines step-by-step procedures and includes a
181 troubleshooting section, all of our patients received some level of assistance from our
182 administrative coordinators via telephone in establishing VC. Minor technical issues on the
183 patient's end such as poor sound quality or intermittent screen freezing were reported during
184 15% of VC (Table 3). Initially, we also encountered in-hospital technical difficulties caused by
185 the VC tool triggering our institution's firewall, which required intervention by our IT staff. The
186 high data volume required for VC also challenged our institution's internet connection,
187 especially during peak use times. Scheduling VC in the afternoon partially alleviated this
188 problem.

189 In 8 patients, video consultation failed due to either patients' lack of necessary equipment or
190 due to technical difficulties. Three patients refused VC for personal reasons (Table 4).
191 Altogether, VC was successfully established in 75/86 (87%) cases. The median age of

192 patients where VC was not established was 62 years, 8 years older than the median age of
193 patients with whom VC was successfully implemented.

194

195

196 **Discussion**

197 To our knowledge, this is the largest study on the implementation of VC in respiratory
198 medicine during the COVID-19 pandemic. VC increased in our center for follow-up care post
199 LTx during the study period while OSV declined. One third of VC occurred due to clinical
200 indication. Overall satisfaction with VC was high.

201 There is currently one published study evaluating VC in transplant patients. In a randomized
202 controlled trial, the readmission rate in 100 recent liver transplant recipients was lower in
203 patients receiving telemedicine in addition to standard of care (SOC) compared to patients
204 receiving SOC only²⁰.

205 Outside the field of transplant medicine, VC has been studied in a variety of clinical contexts.
206 In the home management of 35 newborns with severe heart defects, VC proved superior to
207 both SOC and telephone consultation in reducing the rate of readmission. This study
208 reported technical difficulties in 17% of VC, which is similar to the 15% rate we observed²¹. A
209 majority of studies comparing VC to OSV have been conducted in the field of mental health²².
210 While conclusions from these studies are limited by small sample size, the reported patient
211 satisfaction rates are high²³.

212 Recently, an American group reported on the implementation of VC in the care of 38 cystic
213 fibrosis patients during a 4-week interval during the COVID-19 pandemic²⁴. This study
214 employed a commercial video chat program that does not conform to European Union GDPR
215 requirements. In this study, VC was performed exclusively in patients without symptoms of
216 infection, leading to 2 changes in medication and 1 OSV as a consequence of VC. Patient
217 satisfaction was not assessed.

218 During the COVID-19 pandemic, a rapid transition to telemedicine was necessary to
219 guarantee the continued care of our LTx patients while limiting their potential exposure to

220 SARS-CoV-2. The observed drop in patient appointments, virtual or in person, during the
221 pandemic reflects an understandable lag in implementing telemedicine rapidly and with little
222 preparation. Until the beginning of the study period described here, none of our patients were
223 seen via VC and no infrastructure for this transition was in place. The precipitous reduction in
224 OSV seen in week 11 and 12 and the subsequent steady rise in VC speaks to the workability
225 of a swift transition (Figure 2). However, specific patient populations continue to require care
226 that cannot be delivered by VC. For example, graft hypoperfusion in the early stage post LTx
227 can lead to the development of airway complications like fibrinous bronchitis and bronchial
228 stenosis, requiring repeated interventional bronchoscopy²⁵. Likewise, the diagnosis of acute
229 allograft rejection often requires bronchoscopic lung tissue biopsy¹⁴ . Among clinically
230 indicated OSV during the study period, the vast majority were for such endoscopic
231 procedures.

232 The success of VC was facilitated by a system of patient-owned monitoring devices (home
233 spirometry, pulse oximetry) to objectively assess patients' vital signs. Thus, we were able to
234 identify hypoxemia in a COVID-19 patient and initiate hospital admission before severe
235 clinical deterioration occurred. The implementation of a standardized symptom questionnaire
236 helped lay the groundwork for VC. The measurement of respiratory rate by VC proved a
237 valuable tool in the clinical assessment of patients. This highlights the advantages of VC in
238 fields that rely heavily on the visual assessment of patients, such as respiratory medicine and
239 infectious disease.

240 The majority of VC resulted in either a change of medication or a recommendation for further
241 diagnostic testing, which required our center's expertise due to the complexity of this patient
242 population. We believe this approach can be translated to other chronic respiratory diseases
243 requiring specialized medical care. However, a close collaboration with physicians local to
244 the patient's place of residence remains paramount, especially when further diagnostic steps
245 or procedures are required. In the context of the pandemic making travel difficult, as well as

246 the risk of nosocomial SARS-CoV-2 infection during a visit to a health care facility, VC
247 represents a balance between access to specialist expertise and exposure prevention.

248 The vast majority of patients were satisfied by both the clinical the technical aspects of VC.
249 This high rate of satisfaction is likely due to the structured approach we employed to ensure
250 a smooth logistical and technical process. However, the lack of response to patient
251 satisfaction questionnaires in 30% of VC patients may have led to an overestimation of
252 patient satisfaction with VC. Reasons for non-response to the patient questionnaire may
253 include disinterest or technological fatigue. One out of eight attempted VC was unsuccessful
254 due to patients' lack of equipment, technical difficulties, or patient refusal. Patients with
255 whom VC was not established tended to be older, underlining the concern that patient age
256 poses a relevant barrier to telemedicine²⁶.

257 It is important to note that Germany has poor digital infrastructure compared to other western
258 European countries, particularly in the health care sector²⁷. However, our overall success in
259 implementing VC highlights the willingness of our patients to transition to a telemedicine
260 approach. VC may meet with even greater success in countries with a more advanced digital
261 infrastructure. Direct data transmission from patient-owned monitoring devices, as is already
262 common in a number of commercial health and fitness devices, could facilitate follow-up care
263 in the future²⁸. There are a variety of additional tools in development to allow more diagnostic
264 steps to be taken remotely. For example, a Belgian group is currently developing a system of
265 remote pulmonary auscultation²⁹. In time, some combination of OSV and VC will likely
266 become standard in a wide range of medical specialties. The current COVID-19 crisis and
267 the attendant shift to telemedicine may well catalyze a new level of acceptance of this
268 technology by patients and physicians alike.

269 In conclusion, we demonstrate that VC can be a valuable tool in the effort to provide quality
270 health care to LTx patients during the COVID-19 pandemic. Our center's experience and the
271 roadmap outlined above provide a framework for the implementation of telemedicine for
272 patients with chronic respiratory diseases. With a possible SARS-CoV-2 vaccine still years

273 away, the risk of morbidity and mortality from COVID-19 will inform decision making in health
274 care systems worldwide for the foreseeable future. In this context, VC will play an important
275 role for physicians treating chronically ill patients, and research investigating best practices
276 and new models of care in this area are more relevant than ever.

277

278 **Conflicts of interest:** The authors have no conflicts to declare.

279 **Funding:** The authors received no specific funding for this work.

280 **Acknowledgements:** We would like to thank our administrative coordinators Konstantina
281 Zang-Pappa, Linda Häslér, Anita Fuhrmann and Bianca Metzdorf for their patience with both
282 patients and physicians. Their persistence and efficiency made our clinic's transition to
283 telemedicine possible.

284 **Figures and Tables: Video Consultation in Lung Transplant Recipients during the**
285 **COVID-19 Pandemic**

286 **Table 1:**

Patient questionnaire	Vital signs
quality of life (visual analogue scale 0-10)	FEV1 home spirometry*
general state of health: improved/stable/worsened	respiratory rate
coughing/sputum, yes/no, onset	pulse, regular/irregular
myalgia, malaise, yes/no, onset	blood pressure
runny or stuffy nose, yes/no, onset	oxygen saturation
sore throat, hoarseness, yes/no, onset	body temperature
fatigue, yes/no, onset	body weight
change in medication, yes/no, detail	
physical fitness (flights of stairs without rest)	
local lab report if available	
current dose of calcineurin inhibitor	

287 *FEV1- forced expiratory volume in one second

288 **Table 1:** Patient assessment during video consultation. Summary of medical history and vital
289 signs gathered systematically during VC

290

291 **Figure 1: Sample photos of video consultation**

292 **Not included in this pre-print manuscript in accordance with MeDxriv’s policy on**
 293 **patient images.**


294 **Table 2: Patient demographics**

	video consultation (n=53)	On-site visits (n=51)	p
Gender, female – n (%)	26 (49%)	24 (47%)	0.838
Age at visit – years			0.844
Median (25, 75 quartile)	54 (43, 60)	55 (50, 61)	
Age at Tx – years			0.117
Median (25, 75 quartile)	49 (34, 57)	53 (46, 59)	
Months after LTx			<0.001
Median (25, 75 quartile)	51 (15, 99)	11 (5, 38)	
Tx procedure – n (%)			0.168
Bilateral	47 (90%)	50 (98%)	
Unilateral	1 (2%)	1 (2%)	
Combined	4 (8%)		
Tx diagnosis – n (%)			0.015
Cystic fibrosis	14 (26%)	3 (6%)	
Fibrosis	15 (28%)	14 (27%)	
Emphysema	13 (25%)	24 (47%)	
Other	11 (21%)	10 (20%)	
CLAD – n (%)	17 (32%)	14 (27%)	0.606
Days since last on-site visit			<0.001
Median (25, 75 quartile)	84 (48, 177)	34 (20, 40)	
Distance to site - kilometers			0.556
Median (25, 75 quartile)	197 (112, 262)	158 (85, 244)	
Contacts during study period - n			0.148
Median (25, 75 quartile)	1 (1, 1)	1 (1, 2)	

295 **Table 2:** LTx = Lung Transplantation, CLAD = Chronic Lung Allograft Dysfunction. P-values
 296 from comparisons between VC group and on-site visit group. Statistical significance between
 297 the groups was assessed using χ^2 for categorical variables or Mann-Whitney U test for metric
 298 variables. A P-value of <0.05 was considered statistically significant. All tests were two sided.

299


300 **Figure 2: Number of physician-patient consultation per week during study period**



301

302 **Fig. 2:** Breakdown of VC and OSV by calendar week. Study period begins March 16th, 2020,
303 corresponding to calendar week 12.

304 **Figure 3: Geographic distribution of patients**



305



306


307 **Figure 3:** Map depicting geographic distribution of patients' location. Oval marker denotes
 308 study site (Hannover Medical School). Grey lines mark state borders.
 309

310 **Table 3: Summary of video consultations**

	Completed video consultations (n=75)
Patient device – n (%)	
Laptop / Computer	59 (79%)
Tablet	3 (4%)
Smartphone	13 (17%)
Duration of contact - minutes	
Median (25, 75 quartile)	27 (19, 34)
Reason for consultation – n (%)	
Routine surveillance	24 (32%)
Follow-up	27 (36%)
Clinical indication	24 (32%)
Availability of diagnostic parameters – n (%)	
Pulse oximetry	60 (80%)
Respiratory rate	67 (89%)
FEV1	66 (88%)
Body temperature	57 (76%)
Pulse	59 (79%)
Patient diary	33 (44%)
Outcome of consultation – n (%)	
Medication changed	27 (36%)
Hospitalization	2 (3%)
On-site visit	3 (4%)
Visit local practitioner	14 (19%)
No specific measures	28 (38%)
Reported technical problems during consultation – n (%)	
e.g. poor sound, frozen picture	11 (15%)

311
 312 **Table 3:** Summary of video consultations. FEV1 = Forced expiratory one second capacity
 313

314
 315
 316 **Figure 4: Patient satisfaction with video consultation**



317
318 **Figure 4: Patient-reported satisfaction (n=38)**

319 Boxplots show patient satisfaction as measured on a visual analogue scale (VAS)

320 **Tab. 4: Summary of attempted contacts**

	Attempted video consultations (n=86)
Completed video consultations – n (%)	75 (87%)
Failed video consultations – n (%)	11 (13%)
Reason for failure – n (%)	
Technical problems	6 (55%)
Missing devices	2 (18%)
Patient refused video consultation	3 (27%)

321

322

323 **References**

324

325 1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. *Acta Biomed.*

326 2020;91(1):157-160. doi: 10.23750/abm.v91i1.9397 [doi].

327 2. Kutikov A, Weinberg DS, Edelman MJ, Horwitz EM, Uzzo RG, Fisher RI. A war on two

328 fronts: Cancer care in the time of COVID-19. *Annals of Internal Medicine.* . <https://www->

- 329 [1ncbi-1nlm-1nih-1gov-1du2glhaq7162.han.mh-hannover.de/pmc/articles/PMC7133056/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133056/).
- 330 Accessed May 1, 2020. doi: 10.7326/M20-1133.
- 331 3. Tapper EB, Asrani SK. COVID-19 pandemic will have a long-lasting impact on the quality
332 of cirrhosis care. *J Hepatol*. 2020. doi: S0168-8278(20)30217-8 [pii].
- 333 4. Paganini M, Conti A, Weinstein E, Della Corte F, Ragazzoni L. Translating COVID-19
334 pandemic surge theory to practice in the emergency department: How to expand structure.
335 *Disaster medicine and public health preparedness*. 2020:1-10.
336 <https://www.ncbi.nlm.nih.gov/pubmed/32216865>. doi: 10.1017/dmp.2020.57.
- 337 5. AMA quick guide to telemedicine in practice. American Medical Association Web site.
338 [https://www.ama-assn.org/practice-management/digital/ama-quick-guide-telemedicine-](https://www.ama-assn.org/practice-management/digital/ama-quick-guide-telemedicine-practice)
339 [practice](https://www.ama-assn.org/practice-management/digital/ama-quick-guide-telemedicine-practice). Accessed May 10, 2020.
- 340 6. 1, J. Hosp Med 2020 May;15:302-304 Published online first April. Keep calm and log on:
341 Telemedicine for COVID-19 pandemic response. *Journal of Hospital Medicine*. 2020;15(5).
342 [https://www-1journalofhospitalmedicine-1com-1du2glhvbae3e.han.mh-](https://www-1journalofhospitalmedicine-1com-1du2glhvbae3e.han.mh-hannover.de/jhospmed/article/220018/hospital-medicine/keep-calm-and-log-telemedicine-covid-19-pandemic-response)
343 [hannover.de/jhospmed/article/220018/hospital-medicine/keep-calm-and-log-telemedicine-](https://www-1journalofhospitalmedicine-1com-1du2glhvbae3e.han.mh-hannover.de/jhospmed/article/220018/hospital-medicine/keep-calm-and-log-telemedicine-covid-19-pandemic-response)
344 [covid-19-pandemic-response](https://www-1journalofhospitalmedicine-1com-1du2glhvbae3e.han.mh-hannover.de/jhospmed/article/220018/hospital-medicine/keep-calm-and-log-telemedicine-covid-19-pandemic-response). Accessed May 10, 2020. doi: 10.12788/jhm.3419.
- 345 7. Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the
346 severity of covid-19: A systemic review and meta-analysis. *J Med Virol*. 2020;n/a.
347 <https://doi.org/10.1002/jmv.25889>. doi: 10.1002/jmv.25889.
- 348 8. Sweiss NJ, Korsten P, Syed H, et al. When the game changes: Guidance to adjust
349 sarcoidosis management during the COVID-19 pandemic. *Chest*. 2020. doi: S0012-
350 3692(20)30778-9 [pii].

- 351 9. Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease
352 2019 (COVID-19) infection. *Int Urol Nephrol*. 2020. doi: 10.1007/s11255-020-02451-9 [doi].
- 353 10. Extance A. Covid-19 and long term conditions: What if you have cancer, diabetes, or
354 chronic kidney disease? *BMJ*. 2020;368:m1174.
355 <http://www.bmj.com/content/368/bmj.m1174.abstract>. doi: 10.1136/bmj.m1174.
- 356 11. Sen-Crowe B, McKenney M, Elkbuli A. Social distancing during the COVID-19
357 pandemic: Staying home save lives. *Am J Emerg Med*. 2020. doi: S0735-6757(20)30221-7
358 [pii].
- 359 12. Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients:
360 Initial report from the US epicenter. *American Journal of Transplantation*. ;n/a(n/a).
361 <https://onlinelibrary.wiley.com/doi/abs/10.1111/ajt.15941>. Accessed May 1, 2020. doi:
362 10.1111/ajt.15941.
- 363 13. Adegunsoye A, Strek ME, Garrity E, Guzy R, Bag R. Comprehensive care of the lung
364 transplant patient. *Chest*. 2017;152(1):150. [https://www-ncbi-nlm-nih-gov-](https://www-ncbi-nlm-nih-gov-1du2glhaqf743.han.mh-hannover.de/pmc/articles/PMC6026268/)
365 [1du2glhaqf743.han.mh-hannover.de/pmc/articles/PMC6026268/](https://www-ncbi-nlm-nih-gov-1du2glhaqf743.han.mh-hannover.de/pmc/articles/PMC6026268/). Accessed May 4, 2020. doi:
366 10.1016/j.chest.2016.10.001.
- 367 14. Hachem RR. Acute rejection and antibody-mediated rejection in lung transplantation.
368 *Clinics in Chest Medicine*. 2017;38(4):667-675.
369 <http://www.sciencedirect.com/science/article/pii/S0272523117300746>. Accessed May 4,
370 2020. doi: 10.1016/j.ccm.2017.07.008.
- 371 15. Nosotti M, Tarsia P, Morlacchi LC. Infections after lung transplantation. *Journal of*
372 *Thoracic Disease*. 2018;10(6):3849. <https://www-ncbi-nlm-nih-gov->

- 373 [1du2glhaqf743.han.mh-hannover.de/pmc/articles/PMC6051843/](https://doi.org/10.21037/jtd.2018.05.204). Accessed May 4, 2020. doi:
374 10.21037/jtd.2018.05.204.
- 375 16. Armfield NR, Bradford M, Bradford NK. The clinical use of Skype—For which patients,
376 with which problems and in which settings? A snapshot review of the literature. *International*
377 *Journal of Medical Informatics*. 2015;84(10):737-742.
378 <https://www.clinicalkey.es/playcontent/1-s2.0-S1386505615300113>. doi:
379 10.1016/j.ijmedinf.2015.06.006.
- 380 17. Langarizadeh M, Moghbeli F, Aliabadi A. Application of ethics for providing
381 telemedicine services and information technology. *Medical Archives*. 2017;71(5):351.
382 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723167/>. Accessed May 4, 2020. doi:
383 10.5455/medarh.2017.71.351-355.
- 384 18. Greenhalgh T, Wherton J, Shaw S, Morrison C. Video consultations for covid-19. *BMJ*.
385 2020;368:m998. <http://dx.doi.org/10.1136/bmj.m998>. doi: 10.1136/bmj.m998.
386
- 387 19. Kugler C, Fuehner T, Dierich M, et al. Effect of adherence to home spirometry on
388 bronchiolitis obliterans and graft survival after lung transplantation. *Transplantation*.
389 2009;88(1):129-134. doi: 10.1097/TP.0b013e3181aad129 [doi].
- 390 20. Lee T, Kaiser T, Alloway R, Woodle E, Edwards M, Shah S. Telemedicine based remote
391 home monitoring after liver transplantation: Results of a randomized prospective trial. *Annals*
392 *of Surgery*. 2019;270(3):564-572. <https://www.ncbi.nlm.nih.gov/pubmed/31356267>. doi:
393 10.1097/SLA.0000000000003425.
- 394 21. McCrossan B, Morgan G, Grant B, et al. A randomised trial of a remote home support
395 programme for infants with major congenital heart disease. *Heart*. 2012;98(20):1523-1528.

396 <https://heart.bmj.com/content/98/20/1523>. Accessed May 1, 2020. doi: 10.1136/heartjnl-2012-
397 302350.

398 22. Abimbola S, Keelan S, Everett M, et al. The medium, the message and the measure: A
399 theory-driven review on the value of telehealth as a patient-facing digital health innovation.
400 *Health Economics Review*. 2019;9. [https://www-1ncbi-1nlm-1nih-1gov-
401 1du2glhaq7143.han.mh-hannover.de/pmc/articles/PMC6734475/](https://www-1ncbi-1nlm-1nih-1gov-1du2glhaq7143.han.mh-hannover.de/pmc/articles/PMC6734475/). Accessed May 1, 2020. doi:
402 10.1186/s13561-019-0239-5.

403 23. Backhaus A, Agha Z, Maglione ML, et al. Videoconferencing psychotherapy: A
404 systematic review. *Psychol Serv*. 2012;9(2):111-131. doi: 10.1037/a0027924 [doi].

405 24. Compton M, Soper M, Reilly B, et al. A feasibility study of urgent implementation of
406 cystic fibrosis multidisciplinary telemedicine clinic in the face of COVID-19 pandemic:
407 Single-center experience. *Telemed J E Health*. 2020. doi: 10.1089/tmj.2020.0091 [doi].

408 25. Crespo MM, McCarthy DP, Hopkins PM, et al. ISHLT consensus statement on adult and
409 pediatric airway complications after lung transplantation: Definitions, grading system, and
410 therapeutics. *The Journal of Heart and Lung Transplantation*. 2018;37(5):548-563.
411 [https://www.jhltonline.org/article/S1053-2498\(18\)31349-4/abstract](https://www.jhltonline.org/article/S1053-2498(18)31349-4/abstract). Accessed May 9, 2020.
412 doi: 10.1016/j.healun.2018.01.1309.

413 26. Kruse CS, Karem P, Shifflett K, Vegi L, Ravi K, Brooks M. Evaluating barriers to
414 adopting telemedicine worldwide: A systematic review: *Journal of Telemedicine and
415 Telecare*. 2016.

416 [https://journals.sagepub.com/doi/10.1177/1357633X16674087?url_ver=Z39.88-
417 2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dwww-1ncbi-1nlm-1nih-1gov-](https://journals.sagepub.com/doi/10.1177/1357633X16674087?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dwww-1ncbi-1nlm-1nih-1gov-)

- 418 [1du2glhaq2051.han.mh-hannover.de](https://doi.org/10.1177/1357633X16674087). Accessed Apr 28, 2020. doi:
419 10.1177/1357633X16674087.
- 420 27. Nohl-Deryk P, Brinkmann JK, Gerlach FM, Schreyogg J, Achelrod D. Barriers to
421 digitalisation of healthcare in germany: A survey of experts. *Gesundheitswesen*.
422 2018;80(11):939-945. doi: 10.1055/s-0043-121010 [doi].
- 423 28. Hickey AM, Freedson PS. Utility of consumer physical activity trackers as an intervention
424 tool in cardiovascular disease prevention and treatment. *Progress in Cardiovascular Diseases*.
425 2016;58(6):613-619. <http://www.sciencedirect.com/science/article/pii/S0033062016300160>.
426 Accessed May 4, 2020. doi: 10.1016/j.pcad.2016.02.006.
- 427 29. Steckel J, CoSys-Lab. Project CORELSA – the open-source remote lung sound monitor system.
428 [https://www.uantwerpen.be/en/about-uantwerp/faculties/faculty-of-applied-engineering/news-](https://www.uantwerpen.be/en/about-uantwerp/faculties/faculty-of-applied-engineering/news-and-activities/news/project-corelsa/)
429 [and-activities/news/project-corelsa/](https://www.uantwerpen.be/en/about-uantwerp/faculties/faculty-of-applied-engineering/news-and-activities/news/project-corelsa/) Web site.
430 https://www.youtube.com/watch?v=8lRvM3xHisY&feature=emb_title. Updated 2020. Accessed May
431 1, 2020.
- 432